75338-17-9

Upstream product

• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 67-56-1 methanol 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 38330-80-2 monomethyl monopotassium malonate 
• 137052-08-5 1-(tetrahydro-2H-pyran-4-yl)ethan-1-one 
• 616-38-6 carbonic acid dimethyl ester 

Relevant academic research and scientific papers

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series

As part of our effort toward developing an effective therapeutic agent for c-Met-dependent tumors, a pyrazolone-based class II c-Met inhibitor, N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2- phenyl-2,3-dihydro-1H-pyrazole-4-c

2-SUBSTITUTED-3-(4-TETRAHYDROPYRANYL)-3-OXOPROPANOIC ESTER AND PROCESS FOR PRODUCING THE SAME

This invention provides a 2-substituted-3-(4-tetrahydropyranyl)-3-oxopropanoic ester represented by general formula (1) wherein Y represents a halogen atom or an acyloxy group, and R represents a hydrocarbon group, and a process for producing the same.

PROCESSES FOR PRODUCING ALKYL 3-(4-TETRAHYDROPYRANYL)-3-OXOPROPIONATE COMPOUND AND 4-ACYLTETRAHYDROPYRAN

The present invention is to provide a process for preparing an alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound represented by the formula (1): wherein R1 and R2 may be the same or different from each other, and represent a group which does not participate in the reaction, and R1 and R2 may be bonded to form a ring, and the ring may contain a hetero atom(s), and R3 represents a hydrocarbon group, which comprises reacting 4-acyltetrahydropyran represented by the formula (2): wherein R1 and R2 have the same meanings as defined above, and a carbonic acid diester represented by the formula (3): wherein R3 has the same meanings as defined above, and two R3s may be bonded to each other to form a ring, in the presence of a base, and a process for preparing 4-acyltetrahydropyran.